NSE: SYNGENE | BSE: 539268

Expensive Performer

Download real time

716.00 11.55 (1.64%)

25.46% Fall from 52W High

647.4K NSE+BSE Volume

NSE 21 Mar, 2025 3:31 PM (IST)

28,821.6

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Syngene International Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for SYNGENE, BSE:539268 Syngene International Ltd.

Syngene International Ltd.

24 Jan 2019, 12:00AM

716.00

1.64%

Syngene International Ltd

Buy: Syngene International Ltd.

ICICI Securities Limited

Syngene's Q3FY19 results were a mixed bag. While revenues and net profit were above I-direct estimates, EBITDA margins were lower than our estimates mainly due to lower gross margins Revenues grew 20.5% YoY to | 467.1 crore (I-direct estimate: | 431 crore) mainly on the back of traction in 1) accelerating growth in Discovery Services and Biologics businesses, 2) scientist ramp-up and 2) favourable currency movement (6% YoY). EBITDA margins contracted 251 bps to 30% YoY (I-direct estimate:...

Number of FII/FPI investors increased from 337 to 359 in Dec 2024 qtr.

Syngene International Ltd.

26 Oct 2018

716.00

1.64%

Syngene International Ltd

Buy: Syngene International Ltd.

ICICI Securities Limited

Integrated business model, customer stickiness to the fore SIL's revenues grew at ~21% CAGR in FY13-18 to | 1423 crore due to new client addition on a regular basis and scaled up revenues from existing clients led by integrated service offerings, high data integrity ethos and continuous endeavour to move up the value chain. The capabilities have been vindicated by proven customer stickiness as eight of the top 10 global pharma companies have been availing the services for the last five years. The proposed foray into contract manufacturing...

Syngene International Ltd. is trading above its 30 day SMA of 694.8

Syngene International Ltd.

27 Jul 2018

716.00

1.64%

Syngene International Ltd

Buy: Syngene International Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 39.5% YoY to | 406 crore (I-direct estimate: | 426 crore) mainly on the back of 1) | 40 crore of one-off raw material pass through 2) traction in biologics manufacturing, discovery services and chemical development services, 3) lower base of Q1FY18 (fire incident impact) and 4) favourable currency movement EBITDA margins declined 608 bps to 26.9% YoY (I-direct estimate: 32.2%) mainly due to pass through of raw material billing...

Syngene International Ltd. is trading above its 30 day SMA of 694.8

Syngene International Ltd.

27 Apr 2018

716.00

1.64%

Syngene International Ltd

Buy: Syngene International Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 41% YoY to | 409 crore (I-direct estimates: | 381 crore) mainly due to lower base of Q4FY17 (fire incident impact) and strong growth in chemical development and discovery services supported by biologics business EBITDA margins declined 281 bps to 31.6% YoY (I-direct estimate: 33.1%) mainly due to higher other expenses. EBITDA increased 29% YoY to | 129 crore (I-direct estimates: | 126 crore...

Syngene Internationa.. has an average target of 1030.00 from 1 broker.

Syngene International Ltd.

30 Jan 2018

716.00

1.64%

Result Update:Syngene Intl.

Hold: Syngene International Ltd.

Axis Direct

Syngene posted strong Q3 revenue growth of 17% YoY (~5% ahead of our estimate). EBITDA margin at 32.5% was weighed down by higher growth in staff cost (19% YoY) and other expenses (24% YoY).

Syngene International Ltd. is trading below its 50 day SMA of 733.6

Syngene International Ltd.

29 Jan 2018

716.00

1.64%

Syngene International Ltd

Buy: Syngene International Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 17% YoY to | 388 crore, above I-direct estimate of | 372 crore, driven by a strong performance in the chemicals business from the development & manufacturing vertical and continued traction in the discovery vertical EBITDA margins declined 144 bps to 32.5% YoY (I-direct estimate: 33%) mainly due to higher employee and other expenses. EBITDA grew 12% YoY to | 126.1 crore (I-direct estimate: | 123 crore)...

Syngene International Ltd. is trading below its 50 day SMA of 733.6

Syngene International Ltd.

10 Jan 2018

716.00

1.64%

Visit Note:Syngene Intl.

Mgmt Note: Syngene International Ltd.

Axis Direct

Syngene is expected to post stronger growth from H2FY18 given (1) most of the business impacted by fire incident in Dec'16 will be generating revenue from Q3/ Q4FY18, (2) addition of large scale commercial manufacturing of intermediates and API's for innovator companies

Syngene International Ltd. is trading below its 50 day SMA of 733.6

Syngene International Ltd.

02 Nov 2017

716.00

1.64%

Result Update:Syngene Intl.

Hold: Syngene International Ltd.

Axis Direct

Q2FY18 revenue grew 11% YoY (14% in cc terms), as growth is accelerating after the fire incident (6% YoY in Q1). EBITDA margin was healthy at 33.9% despite 22% YoY growth in staff cost and 14% YoY growth in other expenses. Revenue grew 12% YoY in cc terms in H1FY18.

Number of FII/FPI investors increased from 337 to 359 in Dec 2024 qtr.

Syngene International Ltd.

26 Oct 2017

716.00

1.64%

Syngene International Ltd

Buy: Syngene International Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 11% YoY to | 335 crore (I-direct estimate: | 320 crore) due to strong performance in development & manufacturing services and sustained growth in dedicated R&D; centres Gross margins improved 204 bps YoY to 76.1% but EBITDA margins declined 99 bps to 33.9% YoY (I-direct estimate: 33%) mainly due to higher employee expenses. EBITDA in value terms grew 7.5% YoY to | 114 crore (I-direct estimate: | 106 crore)...

Number of FII/FPI investors increased from 337 to 359 in Dec 2024 qtr.

Syngene International Ltd.

02 Aug 2017

716.00

1.64%

Result Update - Syngene International

Hold: Syngene International Ltd.

Axis Direct

Q1FY18 revenue grew 6% YoY (10% in cc terms) vs. 11% decline in Q4FY18 on recovery of 11% of sales which was affected by fire incident along with new capacity additions. Despite 16% YoY growth in staff cost, EBITDA margin was steady at 33% led by lower other expenses (due to hedging gains).

Number of FII/FPI investors increased from 337 to 359 in Dec 2024 qtr.

No results found

Is Syngene International Ltd. worth buying?

228 Votes:

Buy 75.44%

Sell 14.91%

Hold 9.65%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf